INmune Bio, Inc. Announces Lead Drug Candidate XPro1595 Receives Chemical Drug Name pegipanermin from USAN

Stock Information for INmune Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About INmune Bio Inc.

INmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy
INmune Bio Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro(TM)
INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
INmune Bio to Participate in Baird's Biotech Discovery Series Webcast on February 13, 2024
INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer's Disease Program

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.